SEARCH BUTTON
HOME > IQS TECH TRANSFER > TEAM > Benjamí Oller-Salvia, PhD

Benjamí Oller-Salvia, PhD

Assistant Professor
+34932672000

RESEARCH LINES

  • Development of peptides for biomedical applications.
  • Generation of selectively modified therapeutic proteins by genetic code expansion and bioorthogonal chemistry.
  • Design of vectorised drug delivery systems, mainly targeting the brain.
  • Development of stimuli-responsive proteins and nanomaterials.

 

MEMBER OF:

GEMAT

Grup d'Enginyeria de Materials

School of Engineering

Materials Engineering

Its activities focus on three main areas: the development of new functional materials, surface engineering and biomaterials.

LATEST PROJECTS

APTIBody (Nanoterapias de Glioma)

Estrategia para generar anticuerpos activables y su aplicación para dirigir nanoterapias génicas a células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)

PRO-ANTIBODY (Activación selectiva de Anticuerpos contra el Glioblastoma)

Desarrollo de anticuerpos activables para la administración de terapias génicas en las células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)

ADC2GBM (Development of brain-permeable masked nanobody-drug conjugates to eliminate glioma stem cells)

Innovative formulation to treat glioma using brain-permeable masked nanobody-drug conjugates.
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
1 2
Search more projects

LINKED NEWS

Research

New Peptide and Protein Characterization and Purification Instruments

18/05/2022
IQS has acquired three chromatography instruments for peptide and protein characterization and purification, with funding from the Fundación “la Caixa” Junior Leader Fellowships programme.
READ FULL NEW
Research

Activatable antibodies in targeted therapies

18/02/2022
Dr Oller from IQS has recently received a grant from the Semilla programme with the Spanish Cancer Society (AECC) to work on new types of activatable antibodies against a specific marker of resistant cancer cells.
READ FULL NEW
Research

Activatable Antibodies to Increase Selectivity for Brain Tumour Therapies

19/10/2021
In the Materials Engineering Group (GEMAT) at the IQS School of Engineering, the team led by Dr Benjami Oller Salvia is working to take on two of the great challenges with GBM therapies.
READ FULL NEW
Search all news